Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
about
Belimumab for systemic lupus erythematosusCurrent and emerging treatment options in the management of lupusKey issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implicationsBelimumab in systemic lupus erythematosusCytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus ErythematosusUse of biologics in SLE: a review of the evidence from a clinical perspectiveB-cell survival factors in autoimmune rheumatic disordersBelimumab in systemic lupus erythematosus: a perspective reviewEffect of TACI signaling on humoral immunity and autoimmune diseasesUnmet medical needs in systemic lupus erythematosusFollicular Helper T Cells in Systemic Lupus Erythematosus: Why Should They Be Considered as Interesting Therapeutic Targets?Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus ErythematosusA phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusThe pathogenesis of systemic lupus erythematosus—an updateSafety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.Phenotypic characterization of autoreactive B cells--checkpoints of B cell tolerance in patients with systemic lupus erythematosusInvestigations of a rabbit (Oryctolagus cuniculus) model of systemic lupus erythematosus (SLE), BAFF and its receptors.Pathways leading to an immunological disease: systemic lupus erythematosus.Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?Management of ANCA-associated vasculitis: Current trends and future prospectsDysregulated cytokine production by dendritic cells modulates B cell responses in the NZM2410 mouse model of lupusBAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitisProinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flareBAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.Optimal management of fatigue in patients with systemic lupus erythematosus: a systematic review.A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.Belimumab for the treatment of systemic lupus erythematosus.Active systemic lupus erythematosus is associated with a reduced cytokine production by B cells in response to TLR9 stimulation.Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignanciesRenal involvement in autoimmune connective tissue diseases.Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study.Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy.Infection of Female BWF1 Lupus Mice with Malaria Parasite Attenuates B Cell Autoreactivity by Modulating the CXCL12/CXCR4 Axis and Its Downstream Signals PI3K/AKT, NFκB and ERK.B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels.The discovery and development of belimumab: the anti-BLyS-lupus connectionNew treatment options for lupus - a focus on belimumab.Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
P2860
Q24201547-7FBECF98-C7A1-4982-A8EA-266C70D53B24Q26741266-D9CA5995-FD97-4A9E-9E3F-B49560C30681Q26775756-2E9083BD-0963-422F-999D-B6FF5AE3690CQ26778277-B9E9CD3A-8E02-46E6-8C94-1F02E0C3D929Q26782454-35F1E92F-058E-4B0C-9AE3-BCF4A1B5BAEFQ26783652-DD75BAB0-3191-42A2-A4AC-32A030702410Q26796484-8D922D51-59D1-4CC0-AF96-C17FD7DA1F52Q26796486-7DA7FDED-ED0C-4C5B-8EB9-8A5C50D9DC70Q26995571-11C4159F-5EFE-4FAC-B786-409855737F64Q27005906-292709EA-64B2-4152-8F0F-8D0A1E64C198Q28067781-A9914545-9001-4C49-BE42-9600D6E00E12Q28088753-689CC794-EC03-4631-8F34-F53658A05D76Q28254310-393AF668-F58F-4F2B-A831-EAC9E8D29BCBQ29394347-ED2BF302-3156-426A-BF7C-605DCFF01361Q30580226-6FD6B7A1-65CF-4B7E-A659-CD928F0BA506Q30645037-B13FDF89-FE89-4871-89EF-E6FA1E4F6F35Q33458328-E9AA59FC-D33F-4DAE-AA96-A6A7EFAD36FAQ33521234-5939EA8F-6727-4049-96D5-DC1D91EB9D13Q33620555-93170777-1A9A-4BE7-8210-AAEED3C2E03BQ33698040-8F2E4640-074B-425C-9AA2-552573899A73Q33765598-BE874240-CE6D-4F92-89EC-B4E495612EA6Q33947599-3D8AB7BC-CB1A-4AC1-B70B-1B1BC1127180Q34004649-8E3A8E9F-28C7-41AA-9862-F7C5242CBBEEQ34012753-CEC7430F-BB64-4371-949A-4A9CE45460A8Q34025881-AE2A3C73-B23F-4F29-8B5A-BE2B8983F8C4Q34245983-A8C42432-6BB9-46B5-9FE0-E9D8869BD2BCQ34351248-CABD9948-3460-46BB-B944-DB4050082D02Q34416115-C8744FF8-8A7C-4A9A-A602-A672A7C04791Q34455827-4FBD9F3A-3B9B-49A0-84E4-EC435C2F0E2BQ34587471-5B024F8D-9321-4C24-96A8-BC200C626CC5Q34619806-5124D46E-1077-4B8F-BDD2-B97B292FF9A6Q34654954-DFE40A6B-B3A3-4CDE-8CCC-A56F7051CA56Q34960458-273DCB6A-81B8-4026-9251-E525835B5C7DQ34967765-1DDCDD01-D43D-4557-A83B-20D14CE32199Q35008162-A614221D-3014-47A9-AA68-9252CB243D8EQ35536652-7D46FC91-B8AA-4350-9BA1-2E037D18DD00Q35602526-09C6AE97-703B-4030-ADC9-C41269F8250BQ35691272-63B8E66C-0572-454A-B1E6-AEDD365A392DQ35752030-85863210-AC21-4D62-8E19-D8E5B48F6F98Q35761089-5DCC429C-56A5-44E4-81E2-690553D6A063
P2860
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Association of plasma B lympho ...... systemic lupus erythematosus.
@ast
Association of plasma B lympho ...... systemic lupus erythematosus.
@en
Association of plasma B lympho ...... systemic lupus erythematosus.
@nl
type
label
Association of plasma B lympho ...... systemic lupus erythematosus.
@ast
Association of plasma B lympho ...... systemic lupus erythematosus.
@en
Association of plasma B lympho ...... systemic lupus erythematosus.
@nl
prefLabel
Association of plasma B lympho ...... systemic lupus erythematosus.
@ast
Association of plasma B lympho ...... systemic lupus erythematosus.
@en
Association of plasma B lympho ...... systemic lupus erythematosus.
@nl
P2093
P356
P1476
Association of plasma B lympho ...... systemic lupus erythematosus.
@en
P2093
John Zhong
Marc Chevrier
Virginia Recta
W Joseph McCune
William Freimuth
William Stohl
Winn Chatham
P304
P356
10.1002/ART.23678
P577
2008-08-01T00:00:00Z